文献速递白血病造血干细胞移植与细胞治疗

阿扎胞苷单药治疗初诊幼年型粒单核细胞白血病:AZA-JMML-001 II期试验

Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
PubMed 文献 · Blood Adv · 2021-01-01

这项II期多中心开放标签研究评估阿扎胞苷单药用于初诊JMML患者HSCT前的安全性和抗白血病活性。17例后续接受HSCT,中位随访23.8个月时14例(82%)无白血病生存。

要点

  • 阿扎胞苷75 mg/m2 IV d1-7/28天方案在初诊JMML患儿中耐受良好。
  • 3周期后61%患儿达临床部分缓解,38%需血小板输注者脱离输注。
  • HSCT后中位随访23.8个月,82%患儿无白血病生存。

核心结论

  • 阿扎胞苷单药是初诊JMML患儿HSCT前的合适治疗选择。
  • 阿扎胞苷为JMML患者在HSCT前提供有价值的临床获益。

研究设计与样本

  • II期、多中心、开放标签研究,评估阿扎胞苷单药在初诊JMML患者HSCT前的安全性和抗白血病活性。
  • 主要终点为3周期治疗后达临床完全缓解(cCR)或临床部分缓解(cPR)的患者数。

主要发现

  • 16例完成3周期,5例完成6周期。
  • 3周期后11例(61%)达cPR,7例(39%)疾病进展。
  • 16例中6例(38%)需血小板输注者在3周期后脱离输注。
  • 全基因组DNA甲基化研究中7例中/低甲基化特征患者均达cPR。
  • 17例接受HSCT,中位随访23.8个月(范围7.0-39.3个月)时14例(82%)无白血病。

关键数值与推荐

  • 阿扎胞苷剂量75 mg/m2,IV,每日一次,d1-7,28天为一周期。
  • HSCT后中位随访23.8个月无白血病生存率82%(14/17)。

临床怎么用

  • 阿扎胞苷单药可作为初诊JMML患儿HSCT前的桥接治疗选项。
  • 治疗3周期后评估缓解情况,达cPR者可考虑推进HSCT。

局限性

  • 该人群长期安全性和疗效尚待充分阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for most children with juvenile myelomonocytic leukemia (JMML). Novel therapies controlling the disorder prior to HSCT are needed. We conducted a phase 2, multicenter, open-label study to evaluate the safety and antileukemic activity of azacitidine monotherapy prior to HSCT in newly diagnosed JMML patients. Eighteen patients enrolled from September 2015 to November 2017 were treated with azacitidine (75 mg/m2) administered IV once daily on days 1 to 7 of a 28-day cycle. The primary end point was the number of patients with clinical complete remission (cCR) or clinical partial remission (cPR) after 3 cycles of therapy. Pharmacokinetics, genome-wide DNA-methylation levels, and variant allele frequencies of leukemia-specific index mutations were also analyzed. Sixteen patients completed 3 cycles and 5 patients completed 6 cycles. After 3 cycles, 11 patients (61%) were in cPR and 7 (39%) had progressive disease. Six of 16 patients (38%) who needed platelet transfusions were transfusion-free after 3 cycles. All 7 patients with intermediate- or low-methylation signatures in genome-wide DNA-methylation studies achieved cPR. Seventeen patients received HSCT; 14 (82%) were leukemia-free at a median follow-up of 23.8 months (range, 7.0-39.3 months) after HSCT. Azacitidine was well tolerated and plasma concentration--time profiles were similar to observed profiles in adults. In conclusion, azacitidine monotherapy is a suitable option for children with newly diagnosed JMML. Although long-term safety and efficacy remain to be fully elucidated in this population, these data demonstrate that azacitidine provides valuable clinical benefit to JMML patients prior to HSCT. This trial was registered at www.clinicaltrials.gov as #NCT02447666.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Niemeyer CM, Flotho C, Lipka DB, et al. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021. PMID: 34297046. doi:10.1182/bloodadvances.2020004144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。